SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)

Also known as: ChAdOx1 nCoV-19 COVID-19 Vaccine AstraZeneca AZD1222

Therapeutic indications

SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is indicated for:

Active immunisation to prevent COVID-19 caused by SARS-CoV-2

Irrespective of gender only Adults (18 years old or older)

SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intramuscular - 0.5 ml once

Contraindications

Active ingredient SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is contraindicated in the following cases:

Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

< Previous: Overview